Post Menopausal Osteoporosis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Post Menopausal Osteoporosis – Pipeline Review, H1 2017’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis

The report reviews pipeline therapeutics for Post Menopausal Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Post Menopausal Osteoporosis therapeutics and enlists all their major and minor projects

The report assesses Post Menopausal Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Enteris BioPharma Inc

Intas Pharmaceuticals Ltd

Ipsen SA

Ligand Pharmaceuticals Inc

Lupin Ltd

NIBEC

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Post Menopausal Osteoporosis - Overview

Post Menopausal Osteoporosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Post Menopausal Osteoporosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development

Amgen Inc

Enteris BioPharma Inc

Intas Pharmaceuticals Ltd

Ipsen SA

Ligand Pharmaceuticals Inc

Lupin Ltd

NIBEC

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Post Menopausal Osteoporosis - Drug Profiles

abaloparatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

calcitonin DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lasofoxifene tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romosozumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teriparatide biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Post Menopausal Osteoporosis - Dormant Projects

Post Menopausal Osteoporosis - Discontinued Products

Post Menopausal Osteoporosis - Product Development Milestones

Featured News & Press Releases

Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

Apr 07, 2017: Osteoporosis drug found safe in long-term trial

Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies

Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab)

Mar 10, 2017: Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC

Feb 01, 2017: Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis

Nov 07, 2016: Amgen To Present Data On Denosumab At ACR/ARHP 2016 Annual Meeting

Oct 19, 2016: Research Reveals How Novel Osteoporosis Drug Increases Bone Mass

Sep 26, 2016: Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab

Sep 19, 2016: Radius Presents Abaloparatide Transdermal Patch Development Program at American Society for Bone and Mineral Research 2016 Annual Meeting

Sep 18, 2016: Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR

Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis

Sep 14, 2016: Amgen to present romosozumab at Investor Call

Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting

Aug 16, 2016: JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Post Menopausal Osteoporosis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Post Menopausal Osteoporosis – Pipeline by Amgen Inc, H1 2017

Post Menopausal Osteoporosis – Pipeline by Enteris BioPharma Inc, H1 2017

Post Menopausal Osteoporosis – Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Post Menopausal Osteoporosis – Pipeline by Ipsen SA, H1 2017

Post Menopausal Osteoporosis – Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Post Menopausal Osteoporosis – Pipeline by Lupin Ltd, H1 2017

Post Menopausal Osteoporosis – Pipeline by NIBEC, H1 2017

Post Menopausal Osteoporosis – Pipeline by Oncobiologics Inc, H1 2017

Post Menopausal Osteoporosis – Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017

Post Menopausal Osteoporosis – Dormant Projects, H1 2017

Post Menopausal Osteoporosis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Post Menopausal Osteoporosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports